



Supplementary Figure 1. ROS induction upon treatment with napabucasin


A




B



A549 (lung)




C




Supplementary Figure 2. Napabucasin and NQO1


A






B




Supplementary Figure 3. NQO1 dependency of napabucasin activity




Supplementary Figure 4. Napabucasin-induced transcriptomic changes



Supplementary Figure 5. Reducing the expression of a variety of oxidoreductases




Supplementary Figure 6. Napabucasin-induced DNA damage



Supplementary Figure 7. Cytoprotective mechanisms

A



B

